{"groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"FG000","title":"Bevacizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: wrong primary"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"64"}],"type":"STARTED"},{"achievements":[{"comment":"Eligible and treated patients.","groupId":"FG000","numSubjects":"62"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on 4/29/2002 and closed to accrual on 8/25/2004 (suspended from 10/6/2003 to 12/1/2003)."}